Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (EXAI) have each received overwhelming approval from their shareholders for the proposed ...
Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will ...
Recursion is a leading clinical stage TechBio company decoding biology to industrialize drug discovery. Central to its mission is the Recursion Operating System (OS), a platform built across diverse ...
Recursion (RXRX) and Exscientia plc (EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Recursion and Exscientia. The transaction is expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results